BioSpace News Archive

The decision to allow the release of Adbry follows positive results from the Phase III ECZTRA trials, which covered almost 2,000 patients living with moderate to severe atopic dermatitis.

BridgeBio Pharma reported topline data from Part A (Month 12) of its Phase III study of acoramidis for symptomatic transthyretin amyloid cardiomyopathy. The drug failed the study arm.

The company was assessing mavrilimumab as a potential therapeutic for COVID-19-related acute respiratory syndrome.

Collegium reached a $2.75 million agreement with a law firm representing 27 U.S. cities, counties and subdivisions related to the opioid crisis and the company’s sale of Xtampza.

Sosei Group Corporation, announced its Chief Financial Officer, Chris Cargill, will present at the 40th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Monday, January 10, 2022.

Telos Partners LLC is pleased to welcome Scott Day to the position of Senior VP and General Manager.

LEO Pharma Inc. announced that the U.S. Food and Drug Administration has approved Adbry™ for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Nykode Therapeutics AS announced the first subject has been dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate in its VB-D-01 Phase 1/2 trial.

RELIEF THERAPEUTICS Holding SA reported that the Swiss Patent Office IPI has announced that it expects to conclude the patent application procedure by January 24, 2022 and to issue the patent entitled, “Vasoactive Intestinal Peptide for the Use in the Treatment of Drug-induced Pneumonitis,” as applied for by Relief’s subsidiary, AdVita Lifescience GmbH, in 2020.

Hologic to Webcast Presentation at the 40th Annual J.P. Morgan Healthcare Conference.